Basic information Safety Supplier Related

NSC-348884

Basic information Safety Supplier Related

NSC-348884 Basic information

Product Name:
NSC-348884
Synonyms:
  • NSC-348884
  • N1,N1,N2,N2-Tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]-1,2-ethanediamine
  • 1,2-EthanediaMine, N,N,N',N'-tetrakis[(5-Methyl-1H-benziMidazol-2-yl)Methyl]- (9CI)
  • CS-2168
  • NSC348884;NSC-348884;NSC 348884
  • 1,2-Ethanediamine, N1,N1,N2,N2-tetrakis[(6-methyl-1H-benzimidazol-2-yl)methyl]-
  • lymphoma,cancer,inhibit,SKOV3,MOSEC/Luc cell,NSC-348884,NSC 348884,LNCaP,doxorubicin,NSC348884,Inhibitor,ES2,small molecular,p53,Apoptosis
  • NSC 348884/NSC348884
CAS:
81624-55-7
MF:
C38H40N10
MW:
636.79
Mol File:
81624-55-7.mol
More
Less

NSC-348884 Chemical Properties

Boiling point:
1001.7±65.0 °C(Predicted)
Density 
1.347
storage temp. 
under inert gas (nitrogen or Argon) at 2-8°C
solubility 
≥63.7 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form 
solid
pka
11.61±0.10(Predicted)
More
Less

NSC-348884 Usage And Synthesis

Uses

NSC348884 is a biochemical which inhibitss NPM oligomer formation, upregulates p53 and induces apoptosis.

Biological Activity

nsc348884 is a nucleophosmin inhibitor.nucleophosmin is identified as a multifunctional nucleolar phosphoprotein, which is dysregulated in human malignancies resulting in anti-apoptosis and differentiation inhibition.

in vitro

nsc348884, which was identified as a putative nucleophosmin small molecular inhibitor, was found to be able to disrupt a hydrophobic pocket that was required for oligomerization, and nsc348884 could also inhibit the cell proliferation in distinct cancer cell lines and disrupt nucleophosmin oligomer formation. moreover, the treatment of several cancer cell types with nsc348884 could dose-dependently upregulate p53 and also induce apoptosis that correlated with h2ax phosphorylation, poly(adp-ribose) polymerase cleavage as well as annexin v. furthermore, nsc348884 could also synergize doxorubicin cytotoxicity on the viability of cancer cells [1].

in vivo

previous study showed that the in-vivo intravasation and invasion could be significantly inhibited after the injection of nsc348884 into the tumor-bearing mice. in addition, there was no significant difference in overall cell death that was observed by histology in the treated tumors with the 4-hour brief treatments, indicating that the inhibition seen was specific to migration [2].

IC 50

1.7-4.0 μm for tested cancer cell lines

References

[1] qi w,shakalya k,stejskal a,goldman a,beeck s,cooke l,mahadevan d. nsc348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. oncogene.2008 jul 10;27(30):4210-20.
[2] patsialou a,wang y,lin j,whitney k,goswami s,kenny pa,condeelis js. selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. breast cancer res.2012 oct 31;14(5):r139.

NSC-348884Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Email
isunpharm@qq.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn